- Home
- ESLT vs LEGN Comparison
ESLT vs LEGN Comparison
Compare ESLT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLT
- LEGN
- Stock Information
- Founded
- ESLT 1966
- LEGN 2014
- Country
- ESLT Israel
- LEGN United States
- Employees
- ESLT N/A
- LEGN N/A
- Industry
- ESLT Military/Government/Technical
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ESLT Industrials
- LEGN Health Care
- Exchange
- ESLT Nasdaq
- LEGN Nasdaq
- Market Cap
- ESLT 20.3B
- LEGN 5.4B
- IPO Year
- ESLT 1996
- LEGN 2020
- Fundamental
- Price
- ESLT $449.78
- LEGN $38.96
- Analyst Decision
- ESLT
- LEGN Strong Buy
- Analyst Count
- ESLT 0
- LEGN 12
- Target Price
- ESLT N/A
- LEGN $73.91
- AVG Volume (30 Days)
- ESLT 178.0K
- LEGN 1.6M
- Earning Date
- ESLT 08-13-2025
- LEGN 08-08-2025
- Dividend Yield
- ESLT 0.49%
- LEGN N/A
- EPS Growth
- ESLT 55.53
- LEGN N/A
- EPS
- ESLT 7.89
- LEGN N/A
- Revenue
- ESLT $7,169,721,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ESLT $14.18
- LEGN $65.49
- Revenue Next Year
- ESLT $10.31
- LEGN $53.76
- P/E Ratio
- ESLT $56.68
- LEGN N/A
- Revenue Growth
- ESLT 16.86
- LEGN 112.46
- 52 Week Low
- ESLT $177.85
- LEGN $27.34
- 52 Week High
- ESLT $476.04
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ESLT 58.19
- LEGN 66.26
- Support Level
- ESLT $438.75
- LEGN $34.64
- Resistance Level
- ESLT $458.83
- LEGN $39.88
- Average True Range (ATR)
- ESLT 11.09
- LEGN 1.46
- MACD
- ESLT -0.05
- LEGN 0.37
- Stochastic Oscillator
- ESLT 78.92
- LEGN 87.67
About ESLT Elbit Systems Ltd.
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.